Key Takeaways
- • Canary Capital has proposed a staked Injective (INJ) exchange-traded fund that would stake at least 90% of its INJ holdings under normal conditions, according to the primary source.
- • The proposed fund would trade on the Cboe BZX Exchange under the ticker INJS, but the proposal remains pending regulatory approval.
- • The fund would hold INJ directly and delegate tokens to Injective validators, retaining some unstaked tokens for liquidity and operational needs.
- • The filing carries risks including potential validator penalties, and the fund would not be covered by protections of the Investment Company Act of 1940.
- • As of Oct 14, 2026, INJ traded at Rp138.791 on Pluang with a market cap of Rp14.02 trillion, down 1.20% over the prior day.
Summary
Canary Capital has proposed an exchange-traded fund that would hold Injective (INJ) tokens directly and stake at least 90% of those holdings under normal market conditions, according to the primary source. The fund would delegate tokens to validators on the Injective network to earn staking rewards, while keeping a portion unstaked to meet liquidity and operational needs. The proposed product would list on the Cboe BZX Exchange under the ticker INJS, subject to regulatory approval. The proposal is still pending.
The filing highlights risks associated with the structure, including potential validator penalties. The fund would also lack protections under the Investment Company Act of 1940. The proposal addresses liquidity and unbonding periods so that staking positions align with share redemptions.
Publisher context indicates that Canary Capital filed its third amendment with the SEC for the staked Injective ETF on 13 October 2026, and that the Canary Staked INJ ETF would be an exchange-traded fund issuing shares of beneficial interest. Coverage notes that INJ is among the few major assets with an official ETF filing with the SEC. Injective co-founder and CEO Eric Chen has said he expects U.S. INJ ETFs to launch before 2027. Separately, publisher context references 21Shares' AINJ, a physically backed Injective staking exchange-traded product that reinvests staking yields.
On Pluang, INJ traded at Rp138.791 with a market capitalization of Rp14.02 trillion as of Oct 14, 2026, 22:12 WIB. The token fell 1.20% over the prior day, with 24-hour trading volume of Rp2.81 trillion and order flow of 52% sell and 48% buy. Typical holders keep INJ on Pluang for about 38 days.
The filing highlights risks associated with the structure, including potential validator penalties. The fund would also lack protections under the Investment Company Act of 1940. The proposal addresses liquidity and unbonding periods so that staking positions align with share redemptions.
Publisher context indicates that Canary Capital filed its third amendment with the SEC for the staked Injective ETF on 13 October 2026, and that the Canary Staked INJ ETF would be an exchange-traded fund issuing shares of beneficial interest. Coverage notes that INJ is among the few major assets with an official ETF filing with the SEC. Injective co-founder and CEO Eric Chen has said he expects U.S. INJ ETFs to launch before 2027. Separately, publisher context references 21Shares' AINJ, a physically backed Injective staking exchange-traded product that reinvests staking yields.
On Pluang, INJ traded at Rp138.791 with a market capitalization of Rp14.02 trillion as of Oct 14, 2026, 22:12 WIB. The token fell 1.20% over the prior day, with 24-hour trading volume of Rp2.81 trillion and order flow of 52% sell and 48% buy. Typical holders keep INJ on Pluang for about 38 days.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.